Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that the next Pharmaceutical Price Regulation Scheme considers combination treatments for cancer to be cost-effective.
The Government is committed to supporting the United Kingdom life sciences industry and ensuring that patients can access cost-effective, innovative cancer treatments and technologies at a price the National Health Service can afford. Discussions on a branded medicines voluntary agreement for 2019 onwards are ongoing and are constructive.